Roughly 44% of patients with metastatic melanoma have peritoneal lesions [57], and although B16F10 cells do not encode mutated Braf (equivalent to the BRAFV600E allele found in roughly 40–50% of human melanoma), they have equivalent mutations in the three tumor suppressors, Pten,Cdkn2a, and Trp53 [58] found in human melanomas with WT-BRAF [59, 60]. Here, CDKN2A is linked to neoplasm.